# Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer

> **NCT00780000** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Alvespimycin

## Key facts

- **NCT ID:** NCT00780000
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780000, "Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00780000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*